Clinical Trials · NCT06400615
Study That Tests AD109 in Patients Taking GLP-1 Drugs
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Apnimed
- Enrollment
- 40
- Start date
- May 2024
- Locations
- 4 sites, United States
- Primary endpoint
- Primary Objective (Adverse Events)